Bavituximab Oncology PDF Print E-mail

PS-Targeting Antibodies as Anti-Cancer Agents

Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, helping the tumor to evade immune detection. PS-targeting antibodies override this immunosuppressive signal, activating multiple anti-tumor immune effects.

Data from a series of preclinical studies recently published in the American Association for Cancer Research (AACR) peer-reviewed journal Cancer Immunology Research demonstrated that PS-targeting antibodies, such as bavituximab, mediate important immunostimulatory changes in tumors. These changes include the differentiation of immunosuppressive myeloid derived suppressor cells (MDSCs) and tumor promoting M2 macrophages into tumor-fighting (M1) macrophages and mature dendritic cells that lead to the induction of tumor-specific cytotixic T-cells.

Bavituximab has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of second-line non-small cell lung cancer (NSCLC).

Click here to learn about our bavituximab oncology clinical trials.

Read more about bavituximab's anti-tumor mechanism of action...